Form 8-K - Current report:
SEC Accession No. 0001213900-25-054501
Filing Date
2025-06-16
Accepted
2025-06-16 08:40:11
Documents
13
Period of Report
2025-06-16
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0245818-8k_onconetix.htm   iXBRL 8-K 24033
2 PRESS RELEASE, DATED JUNE 16, 2025 ea024581801ex99-1_onconetix.htm EX-99.1 8025
  Complete submission text file 0001213900-25-054501.txt   200921

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE onco-20250616.xsd EX-101.SCH 3041
4 XBRL LABEL FILE onco-20250616_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE onco-20250616_pre.xml EX-101.PRE 22376
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0245818-8k_onconetix_htm.xml XML 3682
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 251048619
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)